Track protection status across key markets to assess launch feasibility.
It is formulated by 19 pharmaceutical companies such as EXTROVIS, RISING, WATSON LABS INC and others. It is marketed under 5 brand names, including LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE, GLYDO and others. Available in 5 different strengths, such as 2%, 0.5%, 1% and others, and administered through 4 routes including INJECTABLE;INJECTION, JELLY;TOPICAL, SOLUTION;TOPICAL and others.
API availability: Loading API feasibility...
Licensing: 19 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"59233","ingredient":"LIDOCAINE HYDROCHLORIDE","trade_name":"AKTEN","family_id":"eddcba920fe94c16a162","publication_number":"US8759401B2","cleaned_patent_number":"8759401","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-07-24","publication_date":"2014-06-24","legal_status":"Granted"} | US8759401B2 Formulation | 24 Jun, 2014 | Granted | 24 Jul, 2026 | |
{"application_id":"83372","ingredient":"LIDOCAINE HYDROCHLORIDE","trade_name":"ZINGO","family_id":"40f9db0f3eab41449845","publication_number":"US8540665B2","cleaned_patent_number":"8540665","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-10-22","publication_date":"2013-09-24","legal_status":"Granted"} | US8540665B2 | 24 Sep, 2013 | Granted | 22 Oct, 2029 | |
{"application_id":"83368","ingredient":"LIDOCAINE HYDROCHLORIDE","trade_name":"ZINGO","family_id":"40f9db0f3eab41449845","publication_number":"US9358338B2","cleaned_patent_number":"9358338","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-04-27","publication_date":"2016-06-07","legal_status":"Granted"} | US9358338B2 | 07 Jun, 2016 | Granted | 27 Apr, 2035 | |
{"application_id":"83352","ingredient":"LIDOCAINE HYDROCHLORIDE","trade_name":"ZINGO","family_id":"7e5dfad5562f4813ba3c","publication_number":"US9370622B2","cleaned_patent_number":"9370622","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-28","publication_date":"2016-06-21","legal_status":"Expired"} | US9370622B2 | 21 Jun, 2016 | Expired | 28 Sep, 2035 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Lidocaine Hydrochloride
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.